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Abstract
Background: The ending of a clinical trial may be challenging, particularly if staff are required to withdraw the
investigated treatment(s); however, this aspect of trial work is surprisingly under-researched. To address this gap,
we explored the experiences of staff involved in closing out a trial that entailed withdrawal of treatment (insulin
pumps) from some patients.
Methods: Interviews were conducted with n = 22 staff, recruited from seven trial sites. Data were analysed thematically.
Results: Staff described a myriad of ethical and emotional challenges at closeout, many of which had been unforeseen
when the trial began. A key challenge for staff was that, while patients gave their agreement to participate on the
understanding that pump treatment could be withdrawn, they often found themselves benefitting from this regimen in
ways they could not have foreseen. Hence, as the trial progressed, patients became increasingly anxious about
withdrawal of treatment. This situation forced staff to consider whether the consent patients had given at the outset
remained valid; it also presented them with a dilemma at closeout because many of those who had wanted to remain
on a pump did not meet the clinical criteria required for post-trial funding. When deciding whether to withdraw
treatment, staff not only had to take funding pressures and patient distress into account, but they also found themselves
caught between an ethic of Hippocratic individualism and one of utilitarianism. These conflicting pressures and ethical
considerations resulted in staff decision-making varying across the sites, an issue that some described as a further source
of ethical unease. Staff concluded that, had there been more advanced planning and discussion, and greater
accountability to an ethics committee, some of the challenges they had confronted at closeout could have been
lessened or even prevented.
Conclusions: The same kinds of ethical issues that may vex staff at the beginning of a trial (e.g. patients having
unrealistic expectations of trial participation; staff experiencing conflicts between research and clinical roles) may
re-present themselves at the end. To safeguard the wellbeing of staff and patients, greater planning, coordination and
ethical oversight should go into the closeout of trials involving withdrawal of treatment(s).
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Background
Research undertaken with trial participants can be used
to improve recruitment and consenting procedures, offer
insights into how trial interventions are received, aid
interpretation of trial findings and provide recommenda-
tions for conducting future trials [1]. To date, this work
has mostly focused on patients’ understandings and ex-
periences. However, the value of including staff perspec-
tives has also been recognised, with studies highlighting
how staff ’s attitudes and understandings can impact on
recruitment, delivery of trial interventions and, more
latterly, trial outcomes [2–5]. Indeed, studies undertaken
with trial staff have revealed a complex picture, wherein
practical issues, such as having adequate resourcing to
undertake trial work, are interwoven with individuals’
own values, clinical judgment and ethical considerations
[6–8]. For instance, studies have shown that, while trial
staff may adhere to notions of community equipoise,
they may not be in individual equipoise [9], and this may
result in them not approaching certain individuals if they
are concerned that this might result in them being
randomised to treatments that staff see as inappropriate
in their particular case [5–7, 10]. Staff may also be reluc-
tant to approach certain individuals because of concerns
about upsetting or overburdening them [4, 6], reluctance
to admit that they are uncertain about the effectiveness
of treatments [6] and, relatedly, worries about comprom-
ising an on-going therapeutic relationship [4, 6]. Indeed,
it has been shown that because (trial) research and
clinical care have different epistemological underpin-
nings—the former being hypothesis driven, the latter
needs driven—trial staff commonly experience conflicts
between research and clinical roles [11–13]. These con-
flicts may not only impact on recruitment [5, 7, 14], but
also staff members’ adherence to trial protocols as these
require them to follow standardised procedures rather
than provide patients with individualised, tailored care
[2, 8]. As research further suggests, staff's recruitment
practices and adherence to trial protocols may also be
influenced by individual factors, such as their level of
clinical experience [2] and contextual factors, such as
the size and organisation of their clinics [8, 15]. Indeed,
it is because trial recruitment and delivery practices can
be influenced by individual and contextual factors that
commentators have questioned whether trial interven-
tions will work in the same ways and have the same
clinical impact when rolled out into routine clinical
practice [1, 15].
Alongside practical and ethical issues, a small body of
work has drawn attention to attendant emotional
challenges arising for trial staff. For instance, studies
exploring the perspectives of recruiting staff have shown
that individuals may struggle emotionally as well as
intellectually with concepts such as equipoise [7]. Staff
may also find recruitment anxiety provoking because of
experiencing conflicts between research and clinical
roles [6], worrying about upsetting potential recruits [4]
or not meeting recruitment targets [16]. While the main
focus of this work has been on recruitment, it has also
been shown that emotional challenges can extend into
subsequent stages of a trial, such as when staff have to
notify patients about the outcome of randomisation [16]
or encourage patients to remain in a trial when staff do
not see this as being in their best clinical interests [10].
To summarise, research has highlighted the practical,
ethical and emotional challenges that may be encountered
by trial staff. In doing so, this research has also under-
scored the importance of staff being given appropriate
training, education and emotional support to undertake
recruitment and deliver trial interventions in consistent
and unbiased ways [4–7, 9, 16]. However, one key aspect
of trial work remains absent from this research: the close-
out or ending of a trial. This is a striking omission given
that, as some commentators have noted, the ending of a
trial is likely to give rise to practical and ethical challenges,
especially if this requires staff to withdraw treatment and
care from patients [17]. Hence, this article seeks to
address this gap by reporting findings from an interview
study involving staff who were involved in closing out a
trial that required them to withdraw the study treatment,
insulin pumps, from some of those who took part.
The REPOSE trial
The REPOSE (Relative Effectiveness of Pumps Over
MDI and Structured Education) trial was a parallel
group, cluster randomised controlled trial (RCT), con-
ducted in eight centres in the UK between November
2011 and June 2015 [18]. In the UK, where health care is
free at the point of delivery, the majority of adults with
type 1 diabetes use a multiple daily insulin injection
(MDI) regimen and strict clinical criteria, as outlined in
the NICE (English) and SIGN (Scottish) guidelines,
normally have to be met for patients to be eligible for an
insulin pump. The two main criteria for pump eligibility
are: (1) attempts to achieve target haemoglobin A1c
(HbA1c) levels with MDIs result in the person experien-
cing disabling hypoglycaemia or (2) HbA1c levels have
remained high (that is, at 8.5% or above) on MDI
therapy despite a high level of care. As reported in the
REPOSE trial protocol [18], a key reason for the re-
stricted use of insulin pumps in the UK is because
pumps are a much more expensive option than an MDI
regimen. Also, at the time the trial was developed, there
was insufficient evidence to approve extension of pump
therapy to a wider population; indeed, this was a key
rationale for the REPOSE trial being undertaken [18].
The REPOSE trial was designed to determine whether
pump therapy provides added benefit compared to
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optimised MDI therapy after attending a structured
education course [18]. The pumps were provided free of
charge by a pharmaceutical company with a 2-year
warranty and the pump consumables were funded at a
local level [e.g. by Clinical Commissioning Groups
(CCGs), which are clinically led statutory National
Health Service (NHS) bodies responsible for the plan-
ning and commissioning of health care services for their
local area]. Again this funding was restricted to a 2-year
period, as the CCGs (or NHS boards in Scotland) did
not want to commit to providing funding beyond the
duration of the trial. Hence, if clinical staff decided that
a patient should remain on an insulin pump following
closeout from the trial, they had to make a case for local
(e.g. CCG) funding to do this, in much the same ways as
they are required to do for patients they wished to move
onto pump therapy in routine clinical practice.
To be eligible for the trial, patients could not have
used a pump in the previous 3 years or had a preference
for pump therapy over a MDI regimen. Patients were
ineligible if the local investigator determined that they
had a strong clinical need for pump therapy, in line with
NICE or SIGN guidelines (e.g. due to recurrent disabling
hypoglycaemia). Checklists were used to ensure patients
met all trial eligibility criteria, and those taking consent
(local investigators or diabetes educators) discussed key
aspects of the trial to help ensure that patients under-
stood that, because of the restricted nature of the
funding, individuals randomised to pump therapy could
have this treatment withdrawn at the end of the trial.
Following randomisation, recruits attended a 5-day
structured education course called DAFNE (Dose
Adjustment for Normal Eating) to receive comprehen-
sive instruction on how to adjust insulin doses to
achieve optimal blood glucose control. These courses
were delivered by diabetes educators (a diabetes specialist
nurse and a dietician), one or more of whom also took re-
sponsibility for recruitment in each site, supported by the
local investigator (a diabetes consultant) and a central
Clinical Trials Unit (CTU), which was responsible for the
trial’s overall management. Participants remained in the
trial for 2 years and received their diabetes clinical care
from the secondary care centres they usually attended (in
practice, this often meant receiving care from the same
staff who were responsible for delivering the trial). Partici-
pants attended trial appointments, delivered by the educa-
tors, at 6, 12 and 24 months, in order for clinical and
psychological data to be collected.
Prior to closeout, each REPOSE site was advised, as
per the trial’s Standard Operating Procedure (SOP), to
make site-level decisions about which patients should
remain on a pump or be returned to an MDI regimen.
Staff were also reminded that they would have to find
local funding for any individuals they wanted to keep on
pump therapy. The SOP also mandated that patients
could not be told whether they would remain on pump
therapy until after final trial data had been collected, to
avoid biasing trial data collection; specifically, patients’
responses to self-completion questionnaires that
assessed their treatment satisfaction and quality of life.
This interview study was developed after closeout had
begun in some sites and anecdotal reports had been
received from some staff that they were encountering
difficulties withdrawing pump therapy from some
patients. A key aim of this study was to understand and
explore staff experiences of closing out the REPOSE trial
to provide recommendations for training and/or support
that could be offered to staff involved in the closeout of
future trials requiring withdrawal of treatment(s). Ethical
approval for the study was granted by the Centre for
Population Health Sciences Ethics Review Group, the
University of Edinburgh, at the start of June 2015.
Methods
Following receipt of ethical approval, recruitment was
undertaken in seven of the eight REPOSE sites, which
were based in England and Scotland; the eighth site was
not included as it was added at the end of the trial and
only hosted a small number of patients. All staff who
had been involved in closeout (diabetes consultants and
diabetes educators) were sent recruitment packs and
invited to opt in; of the 24 staff approached, 23 opted in
and 21 were interviewed (see Additional file 1: Table S1).
Interviews took place from the end of June 2015 to the
end of August 2015, by which time the trial was in the
final stages of closing out. Interviews were conducted by
NH, an experienced qualitative researcher who was not
a member of the trial team. Interviews were informed by
a topic guide developed in light of literature reviews and
initial reports from staff and revised in light of emerging
findings. Key areas explored included: previous experi-
ences of delivering clinical trials, experiences of recruit-
ing and consenting into REPOSE, preparation and
planning for closeout, how decisions about treatment
allocation were made at the end of the trial and by
whom, experiences of undertaking end-of-trial appoint-
ments and (if relevant) of withdrawing treatment, how
staff felt the closeout of trials involving withdrawal of
treatment(s) could be improved and how any of the
ethical challenges they had encountered at closeout
could be lessened or prevented in future trials. Inter-
views lasted ~60-90 min and were digitally recorded
(with consent) and transcribed in full for in-depth ana-
lysis. By the time recruitment and interviewing were
stopped, data saturation had been achieved, that is no
new findings were identified in new data collected.
The interviews were analysed thematically by JL and
NH using principles informed by the method of constant
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comparison [19]. JL and NH read all interviews through
repeatedly before cross-comparing them to identify
issues and themes that cut across different individuals’
accounts. These individuals then met to discuss their
interpretations and reach agreement on key findings.
Following this meeting, a decision was made to under-
take an additional (comparative) analysis of staff inter-
views according to the trial site to which they belonged,
as the initial analysis had made it apparent that staff
practices and decision-making at closeout were often
mediated and informed by site-specific (i.e. contextual)
factors. JL and NH then developed a coding frame that
captured cross-cutting themes together with the descrip-
tive data needed to allow a ‘thick description’ [20] of the
findings to be provided to readers that was sensitive to
contextual factors. A qualitative analysis software pack-
age (NVivo10) was used to facilitate data coding and re-
trieval; to maximise rigor, both JL and NH were involved
in the data coding process. Coded data sets were sub-
jected to further analyses to enable more nuanced inter-
pretations of the data to be developed and to select
illustrative quotations and descriptive data used as part
of the data reporting process.
To safeguard participants’ confidentiality, pseudonyms
for individuals Dr (Diabetes Consultant) or Ed (Diabetes
Educator) are used, with (A-G) indicating the site to
which they belonged.
Results
Staff provided very rich, candid and sometimes emotion-
ally charged accounts of their experiences of closing out
the REPOSE trial. As well as reinforcing earlier anecdotal
reports that withdrawing pump therapy could be challen-
ging, their interviews revealed big variations in staff
practices and decision-making between (and sometimes
within) the different trial sites. In some sites, staff kept
most or all of their patients on pumps irrespective of
whether they had gained clinical benefit from using this
regimen, whereas in others pump therapy was withdrawn
unless a clear clinical benefit, in line with NICE or SIGN
criteria, could be evidenced. Not only did these variations
in decision-making across (and sometimes within) the dif-
ferent sites come as a surprise to most staff, they also de-
scribed them as having been a source of friction. Staff
accounts also made apparent that, in making their deci-
sions about whether or not to withdraw pump therapy,
they had had to confront ethical and other challenges that
they saw as having arisen directly from the trial, some of
which had been unforeseen when the trial first began.
Below, we explore these findings in more detail before
considering learning points that staff were keen to share
to improve the (ethical) conduct of future trials where
treatment(s) might be withdrawn.
Variations in practices and decision-making at the end of
the trial
The variations in practice and decision-making de-
scribed above, as some staff noted, only became ap-
parent several months after closeout had begun when,
in a monthly trial investigator meeting, a couple of
staff talked about the difficulties they had encoun-
tered taking individual patients off pumps. Indeed, as
Dr G2 noted, it was not until these difficulties had
been raised that they had begun to question their
assumption that co-investigator colleagues would
“fiddle it for the patient” as they had done and allow
those who wished to do so to remain on pump ther-
apy following closeout from the trial:
“I was a bit taken aback when [colleague’s name] said
somebody had walked out and I was also slightly
taken aback when [another colleague’s name] said
she’d stopped the pump and it hadn’t gone down too
well, so clearly others were following the letter of the
procedure, whereas I never thought I would, I thought
I’d fiddle it for the patient because, I mean there are
NICE guidelines, but you can get anybody on a pump
if you really want…I mean you can call me a big softy,
but I think we owe it to our patients to do the best by
them. They live with diabetes 24 hours a day and it’s
terribly demanding and it’s rotten for people and I
think they should be given the support and if they
want to keep the pump they should keep the pump.
And it’s worth remembering that the technology in
diabetes is pretty good value compared to some
very expensive cancer treatments which may only
buy a couple of months of extra life…So I think
that I feel strongly that anything which makes life a
bit better is probably worth it, and if we can get
round the rules if it’s for the benefit of the patient,
I’d always do that.”
This individual’s perspective stood in notable contrast to
that of Dr F, who had removed pumps from the majority
of patients they saw, and who, to justify their decision-
making, highlighted a personal and ethical standpoint that
was cognizant of what they saw as broader financial diffi-
culties within the NHS and, hence, the need to allocate
scarce resources in prudent ways:
“So I feel there are people who need a pump because
without it they’re never going to get their diabetes
right. And there are people who would like one
because it might make it easier or it’s more
convenient or for a variety of reasons. And my
personal view would be that at the moment the NHS
probably can’t afford to provide pumps for the latter.”
(Dr F)
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As Dr F’s comments served to highlight, contextual
factors; specifically, availability of funding for pumps,
could have a substantial impact on staff decision-making
at the end of the trial. Indeed, as the analysis of the
interviews made apparent, staff decision-making was
broadly informed by whether they belonged to sites
where they perceived there to be easy access to pump
funding at the end of the trial (sites B, C, D, E) or those
where access to NHS funding was much more limited
(sites A, G, F). Dr G1 belonged to one of the latter sites,
where, as this health professional described, local fund-
ing constraints, together with the limited availability of
staff with pump training, had had a substantial impact
on their decision-making. This, as Dr G1 described, had
been to withdraw pump therapy unless a clear clinical
benefit could be demonstrated that allowed a case to be
made to the local CCG for on-going funding:
“If pumps were cheaper, if we had more staff who
knew how to help patients, then there would be more
pump use so… there were lots of kind of context to
my decisions.” (Dr G1)
Indeed, this health professional went on to reflect on
how, due to these contextual factors, they had had to
“act as a filter” at the end of the trial because quality of
life was not a criteria that they could use to apply for
pump funding at their site:
“…the bottom line is that we can’t apply for funding
based on quality of life. So no matter how much the
patient tells us that they feel better, the clinician’s not
interested in that at all. So whilst obviously I feel that
quality of life is really important to patients and I
would like to be able to support them in that, the
rules don’t let me.” (Dr G1)
Similar “hard-nosed” (Ed A1) decisions were described
by staff in site A where, again, due to the limited NHS
funding available for insulin pumps in their region, staff
said their decision-making had, by necessity, been
“pretty cut and dried…unless there was a medical reason
or unless they met NICE [criteria] already from a
hypo[glycaemia] point of view, they had to come off.”
(Ed A2)
In other sites, as already indicated, pump funding was
more abundant at the time of closeout. In three cases
this was due to the sites being based in Scotland and the
Scottish government providing a substantial but tempor-
ary injection of funding for insulin pumps, which had
happened to coincide with the ending of the trial: “so
politics, you don’t look a gift horse in the mouth—we
just said ‘yes, we’ll take these thank you very much”
(Dr B). In the fourth site, as the lead investigator
described, “we don’t really have an issue with funding
for pump therapy. We never have had because historically,
when primary care organization first came into existence,
we already had probably 80 people on insulin pump
therapy. So they just picked up the costs of that and
subsequently they’ve just regarded insulin pump therapy
as something they just fund really” (Dr C).
Because funding for insulin pumps was not so
restricted in these sites at the time of closeout, staff,
including Dr E, described how, when they were making
decisions, “we knew there wasn’t going to be any imme-
diate problem here about patients giving the pump back
at the end of the study” (Dr E). As a consequence, staff
also noted how it had been possible for them to base
their decision-making on “much softer criteria” (Dr C),
which took patients’ own preferences and quality of life
considerations into account. Indeed, in such sites, staff,
including Dr D, described how they had used diffuse and
broad-ranging concepts of “doing well” to inform their
decisions, which extended beyond the clinical eligibility
criteria outlined in NICE/SIGN guidelines:
“It’s interesting isn’t it, so doing well might be having
good blood glucose control. But doing well might just
be engaging with their diabetes better than they did
before. So, you know, we had a couple of quite
chaotic people who don’t have perfect glycaemic
control, but they’re testing [their blood glucose levels],
they’re entering information [into the pump] and
they’re keeping in touch with us in a way that before
they weren’t. So I guess doing well can be something
over and above what their blood sugar’s telling us.”
(Dr D)
To justify and explain leniency in their decision-
making at the end of the trial, some such staff also
highlighted discrepancies between the care they had
been able to give patients within the confines of the trial
and that which they were able to provide in everyday
clinical practice within their particular sites. Specifically,
these staff members described how, when funding had
permitted, they had tended to give patients who had not
experienced clinical improvement “the benefit of the
doubt” and “a second chance” by allowing them to re-
main on pump therapy, but with greater clinical support
than had been permitted within the constraints of the
trial protocol. This included Dr D who described how,
in their site, they had “continued pumps in most who
wanted to, even in the few we were slightly worried
about” because “I am not sure our pump group in
RESPOSE did as well as our [patients on] pumps do in
our normal service because we didn’t put in the same
amount of follow-up as we do for people who go onto
pumps in our own service.” A similar course of action
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was reported by Dr C who described having allowed
some patients who had actually experienced a deterior-
ation in their blood glucose control to remain on pump
therapy because they had wanted to give them “a proper
chance, with very intensive management which, probably
within the constraints of the study, I don’t think would
have been appropriate” (Dr C).
Staff reflections on variations in end-of-trial practices
The above variations in practice not only came as a
surprise to most staff, the vast majority also described
them as having been a source of discomfort or, more
specifically, of ethical unease. In some cases, staff, in-
cluding Dr C, simply expressed a general sense of dis-
comfort that such disparities had existed, wherein: “it’s
perhaps unfortunate that, you know, our pump users
have virtually all carried on with the pump, whereas per-
haps (other) pump users have all gone back onto MDI”
(Dr C). In others, staff conveyed more candid views, by
suggesting that colleagues at other sites might have
taken an easy route out, and side-stepped some of the
difficulties they had had to confront, by allowing most
or all of their patients to keep their pumps:
“We had a telephone conference and I got the
impression from that, that certainly some of the other
centres hadn’t really thought about it. They just left
the patients on their pumps. Now that’s my
perception. But I felt, I felt really unsupported. The
big—when I really got upset—this is turning into a
psychotherapy session—when I really got upset was
after the telephone conference, when people kind of
said: ‘well we just didn’t do that’. And I think
yeah—so that was difficult, because I felt we’d done
something different. And we had followed the
protocol…But it didn’t sound as though that had
necessarily been the experience elsewhere.” (Dr F)
As well as questioning the practices of colleagues in
other sites, some individuals indicated that tensions had
developed within their own teams when it was felt that
decision-making had been guided by inconsistent criteria
or, as Ed B1 intimated, it became apparent that team
members might have had different—and potentially
conflicting—values:
“…he [Consultant’s name] certainly came back and
told us all, you know, what his decision was, you
know, he was happy for them all to stay on pumps…
in the end it was his clinical decision but some of us
had reservations. I mean the pump therapy’s it’s
obviously an expensive you know, treatment to be
using with patients…I just wonder with some of them
is that the best use of resources?” (Ed B1)
Others still voiced underlying ethical concerns that,
due to variations in how decisions were made, patients
had not been given fair and equal access to (scarce)
resources at the end of the trial:
“…to a certain extent still, pumps and funding for
various things is a post-code lottery. As you know,
different centres did do things in different ways. And
so I think, I don’t know, potentially, you could kind of
think, ‘well that’s not fair if one centre is just, had kept
everyone on and we haven’t'...And I think the fact we
did have to do it this way, you think, ‘oh that’s a bit
annoying’. And you felt bad for the patients.”
(Ed A2)
Indeed, alongside this concern, which was seen as
having been symptomatic of a broader post-code lottery,
staff identified a number of other issues at closeout that
they saw as having arisen directly from the trial. As will
now be considered, these presented a number of ethical
and emotional challenges to staff, which, in the absence
of advance planning and discussion across the trial sites,
they had attempted to address in a variety of ways and
with what they saw as varying degrees of success.
Ethical and emotional challenges arising from the trial
As described earlier, to be eligible for REPOSE, patients
could not have a treatment preference; patients also gave
their consent on the understanding that pump therapy
could be withdrawn at the end of the trial. However,
staff who had had contact with patients during the trial
noted that, as the trial progressed, most patients
“became very fond of their pumps” as Ed E1 put it and,
hence, as Ed B1 elaborated, they had also made it clear
that they had wanted to keep them:
“They were absolutely fine at the start, they’re like,
‘yeah, yeah whatever’. They didn’t seem perturbed
about that at all…that was to change as time went on.
You know if they’d requested to see us, or at the kind
of routine REPOSE follow-ups, when we asked how
they were feeling about the pump, they all reported
that they loved the pump, that they felt it was making
their life so much easier and that they couldn’t
imagine going back to having to inject multiple times
a day. So they were all very vocal that they really
wanted to stay on their pump, and that they would be
prepared to fight for it if needs be.” (Ed B1)
As these staff went on to suggest, while some patients
might have concealed a preference for a pump when
they were recruited, others appeared to have gained
benefits that they could not have necessarily foreseen.
Such benefits, as Ed B1 observed, were principally those
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relating to improvements in their quality of life because
pumps eased the burden of having to administer
multiple daily injections. As some staff further reflected,
this had presented a predicament and caused them anx-
iety at the end of the trial because, while patients had
benefitted from using a pump, many had not done so in
the clinical ways that could have been used to make a
case to the local NHS funder for on-going use of this
regimen.
“…because we did see patients who things have
improved to, but the pumps, the background rates
were very flat so you could do the same with
injections. But they all liked the pump because there’s
no injections…But it made it tricky at the end when
we had to say to them: well actually you can achieve
this with injections…The trial didn’t take into account
the fact that they were happier on it. They felt calmer
or you know, sort of all those quality of life things.”
(Ed F4)
“I thought it [close-out] would be uncomfortable
because the NICE criteria don’t talk about quality
of life…I was thinking: well there’s going to be lots
of patients that say they feel better. But actually
have they hit any of the hard end points that help
me say: yes you do need now to continue on
pump.” (Dr G1)
Others reflected upon how experiences of observing
patients become more worried and distressed about the
possible removal of the pump as the trial progressed had
forced them to question whether the consent they had
given at the outset remained valid, and, hence, whether
it was ethical to withdraw pump therapy despite patients
having originally agreed to this. Indeed, some health
professionals went as far to question whether patients
had ever really been in a position to make a properly
informed decision, given their lack of experience with
pump therapy prior to the trial, a situation that led some
to suggest that patient anger and upset would be justifi-
able in the event of a pump being withdrawn:
“So basically the patient had taken the decision to
go on knowing that they were probably going to
have to come off at the end of two years. So that
kind of eased my conscience a bit in that the
patients had made that decision themselves. But
again, cause I had that longer experience in pumps
and I knew what I’d seen, I just knew how awful
that was going to be. And I don’t think patients
could possibly have realised that when they agreed
to that happening at the beginning, do you know
what I mean?” (Ed D2)
“I know that when people signed up for the trial they
knew that they might not stay on the pump. But I
suspect that people at that point wouldn’t really have
understood just what an impact that pump has on
their life. So I can understand if somebody was told
they couldn’t keep their pump that they’d be very
upset or angry about it.” (Ed F4)
As well as worrying that patients would be upset or
angry, some staff expressed a strong sense of personal dis-
comfort about the prospect or possibility of withdrawing
treatment from patients who liked it and felt they were
benefitting from it and who, as Ed E1 further noted, had
also given their time to take part in the trial:
“I can see it’s maybe quite cruel to give somebody a
treatment which they feel makes their life much
easier, and then try and take it away from them.”
(Ed D2)
“It was kind of frustrating because they were helping
in a study and you were giving them something which
they felt was a benefit to them and then you were
going to take it away as soon as the study stopped. So
it wasn’t, you know, I don’t know, it just didn’t feel
right to be doing that.” (Ed E1)
Experiences of withdrawing the pump
In line with these staff members’ expectations and
concerns, patients from whom pump therapy was
withdrawn were described as having been “disappointed”
(Ed G), “upset” (Ed A2), “disgruntled” (Ed A1) and
“gutted” (Ed G) with staff, including Ed G, also noting
the personal upset and distress they had themselves
experienced as consequence:
“Certainly, he was gutted, you know, I basically just
didn’t give it back to him. And I gave him the
prescription for insulin inject- pens and discussed
what to start on and how to go- and he was like
looking at me like a, you know, a rabbit caught in the
headlights. And I’m thinking: ‘oh god, this is really
awful.’” (Ed G)
However, some staff also reflected upon how, while
often upset and disappointed, most patients had also
been stoical and accepting of the decision, especially
when these staff members (n = 5) had been involved in a
6-month pilot study that had preceded the main trial. As
these staff noted, their earlier exposure to individuals
who had been angry and distressed about the removal of
pump therapy at the end of the pilot study had alerted
them to the need to devise proactive strategies in the
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main trial to prevent or manage patients’ (potential)
upset and anger at its end:
“We’d learnt a lesson from, I think the pilot of having
a situation where people were really upset about not
being able to keep it despite signing things, having it
written. It was very difficult having somebody in front
of you, crying and getting frustrated and saying all
sorts of things to you, so we were much clearer we
think this time round with, just reminding people of
the rules and we tried to do it each time we met them
as well, reminding them this was a trial and if they
don’t meet NICE criteria [at the end] the pump would
go back.” (Ed F3)
While some staff, including Ed F3, highlighted the
benefits of reminding patients throughout the trial that
pump therapy could be withdrawn so that their expecta-
tions were managed from the outset, others (from site A),
described how they had offered patients a ‘wash out’
period at the end of the trial to help them adapt psycho-
logically and practically to removal of the pump:
“We knew we were going to have difficult
conversations, so we came up with plans of how we
could best do it, so we didn’t just switch them there
and then on the 24 month visit. We said- we
reminded them—we had kind of—you know a few
people were quite upset and grumpy about it. And we
said: ‘look we have some kit we can give you that you
can—we can tide you over for another month or six
weeks, while we sort out your pens and getting you
back—to switch you back onto MDI and doing it in a
supportive as way as possible’. We didn’t, you know,
rip the pump off them at that appointment and say:
‘there’s your pens back, off you go’. And so we
just—having that discussion at the meetings before for
all of them just helped us come up with a kind of
individual plan to sort of damage limitation really.”
(Ed A1)
While such strategies were described as “damage limi-
tation”, staff also noted that they had been relatively ef-
fective in so far as, “although we had some people who
are a bit upset, I don’t think anyone was so disgruntled
that he had to go and fetch [diabetes consultant’s name]
to come and smooth things over” (Ed A1). Indeed, in
cases where these strategies were not employed, due to
lack of advance planning and poor communication
within and across teams, staff described encountering
much more extreme emotional reactions from some
patients. While these staff, like their colleagues, had an-
ticipated that patients would be upset, they described
themselves as having been “utterly ill-prepared” (Dr F)
for the anger and distress that they actually encountered.
This included Dr D who described having felt “over-
whelmed” during a consultation where they had had to
inform a patient that pump therapy would be withdrawn
and that Dr D described as having been “one of the most
uncomfortable things I’ve done for a long time”. As Dr
D went on to elaborate:
“I don’t often have negative interactions with people,
but he was very cross and very angry with me, and
understandably I guess, maybe, you know, he felt
passionately about what he was using. But it was
uncomfortable and I don’t normally feel
uncomfortable in a consultation…But, on this
occasion, I felt really sort of overwhelmed by his
strength of feeling.” (Dr D)
A similar incident was reported by Dr G1, who
described having been taken aback by the degree of
distress and anger exhibited by one individual from
whom they had withdrawn pump therapy:
“The one locally that really didn’t go well, was a
gentleman whose control had got worse on the pump.
He’d had two admissions with DKA [diabetic
ketoacidosis —a life threatening condition]. And I was
explaining that in fact on balance it was actually more
dangerous for him to remain on a pump, cause he
was more likely to be admitted in DKA again on a
pump, because he’d not had any DKAs off the pump.
And he was the one that walked out. He didn’t shout
or give me any indication. He just stood up and said:
‘okay’ and walked out. So obviously he was boiling
underneath and I hadn’t quite appreciated this. And
then his wife just looked at me cause she was totally
shocked when he walked out as well.” (Dr G1)
In site F, where, due to limited communication within
the team, only some patients had been ‘primed’ for close-
out, Dr F also described very negative experiences of with-
drawing treatment, albeit in this site, the full extent of
patients’ anger did not become fully apparent until after
the end of the trial appointments had taken place:
“And I felt that the conversations went reasonably
well, because it was a rational discussion between
adults. I pointed out why I was not recommending
continuation. And I also said very explicitly: ‘you
know, if this doesn’t work, come straight back’. And
then I started to get these messages from my
colleagues that they were being bombarded with
emails about how this was terrible. And that’s when it
all—that’s when, that’s when we realised there was a
problem.” (Dr F)
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Elsewhere in their interview, this health professional
talked about how their colleagues had never actually
given them sight of the emails or separate a letter of
complaint received from another patient, “possibly
because they were being protective of me, or because
the patients had said they didn’t want them to show
them me, but I know they got a lot of abuse from these
patients.” (Dr F).
As Dr F, Dr G1 and Dr D’s accounts make apparent,
not only did some patients exhibit reactions that they
had found very upsetting, they also interpreted patients’
anger and/or subsequent complaints as signalling
strongly that that these patients had felt that they had
failed them in their duty of care. Understandably, to try
to make sense of these kinds of experiences, this group
of individuals tended to provide much more reflective
accounts than colleagues whose end-of-trial encounters
had been more straightforward. In doing so, these indi-
viduals not only speculated that patients had gained un-
anticipated quality of life benefits from using a pump,
but they also reflected upon the possibility that some
might have held a misconception that the (pump) treat-
ment to which they had randomised had been needs
rather than hypothesis driven—a phenomenon termed
the ‘therapeutic misconception’ in the literature [21]. In
developing this line of thinking, Dr G1, for instance,
drew a potential parallel between perceptions and views
of REPOSE participants and those of patients who had
taken part and a recently completed trial (the 5x1 study).
In the latter, as Dr G1 noted, embedded psychosocial
research [22, 23] had shown that many participants had
held the view that the trial arm to which they had been
randomised had enabled them to access the treatment of
greatest personal and clinical benefit:
“We didn’t actually do quite the same thing as we did
with 5x1 where we asked them which arm [DAFNE
delivered over one week, or DAFNE delivered one day
a week over five weeks] they thought was best…In the
5x1 88% said: well this [the arm to which the
participant was randomized] was the best way I can’t
imagine it in the opposite way. And I think if we’d
asked that question here we might have got a similar
result because the people just rationalised that
whatever arm they were randomised to that was how
it was meant to be.” (Dr G1)
Hence, as Dr G1 indicated, not only could a (mis)con-
ception that treatment allocation had been needs driven
potentially help explain patients’ anger when they had
attempted to withdraw it, but also the difficulties staff
had encountered convincing some individuals that they
had not gained clinical benefit from using a pump. A
similar conclusion was reached Dr F, who also drew
upon learning from the 5x1 trial to suggest that a thera-
peutic misconception might help explain why some
patients appeared to have struggled to separate the clin-
ical benefits of using an insulin pump from the clinical
benefits gained from having attended the structured
education (DAFNE) course at the start of a trial:
“…the study that looked at DAFNE given over five
days or given over five weeks × the patients at the end
of that were absolutely adamant that the way they did
it was the best way to do it. And I guess the pump
[REPOSE trial] is the same. So we, because DAFNE is
good, you think that your [pump or MDI] DAFNE is
the way to do it. And I guess that’s what this was. I
mean you know, DAFNE, it was fantastic I loved it.
What I loved was DAFNE with pump. And as a
patient I didn’t distinguish between DAFNE and
pump, they’ll have attributed their benefit to the
pump, whereas the MDI group will have attributed
their benefit to DAFNE. Now that’s only just occurred
to me in talking to you. So, what I thought I was
doing was having an intellectual conversation saying:
‘well actually if there is no clear indication for a
pump, they should try without it’ but that’s not what
their perception will have been; to the person with
diabetes there would have been a feeling of, you,
know what I now regard as my lifeline is being taken
away from me.” (Dr F)
Side stepping ethical issues and emotional challenges at
the end of the trial
Given their concerns about upsetting and angering pa-
tients, it is perhaps unsurprising that staff who belonged
to sites where there was easy access to pump funding at
the time of closeout did not generally withdraw pump
therapy unless there was a compelling health or safety
reason to do so. Indeed, staff in these sites noted that,
by keeping most/all patients on pumps, they had been
able to side step the anguish and upset (both to patients
and themselves) that colleagues in other sites had had to
confront:
“It would have been—I’ll be honest—I would have
been devastated for them…I think if you’ve done
really well with something and you know, you’ve
worked with the team, and worked really hard and
then you’ve had that [pump] taken away from you, I
think that would be awful. And I think, as an
educator, I’d have found that awful as well.” (Ed D2)
“Well I guess if we had been in the same situation as
other centres where there was no funding stream to
continue patients, we would have had to say, ‘sorry, we
don’t have any money for you to continue on this.’
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And I think it would be very difficult. I mean
obviously I would imagine in other places it’s caused a
bit of damage to the doctor or healthcare professional
relationship because there was a sort of building up of
trust going through the study and at of the end of it.”
(Dr B)
Indeed, because of their concerns about damaging
on-going therapeutic relationships, such staff, includ-
ing Dr B, were keen to emphasise that, had they re-
moved pumps from individuals when it was possible
to access on-going funding, they would have failed
them in their duty of care. However, even in those
sites where it had been possible to keep patients on
pump therapy, staff still felt they had not been able
to bypass or address ethical issues altogether. Specif-
ically, staff shared their frustrations and worries that,
because the trial protocol had not permitted them to
tell patients that they could remain on pump therapy
until after final trial data had been collected, patients
had experienced what they saw as avoidable worry
and distress:
“Well I think definitely they should have known
earlier that they were continuing on the pump.
Whether that was at the beginning, or halfway
through, but definitely not leave them for two years
thinking you know, ‘I’m not going to have this pump
at the end of this.’ So I think that was a bit cruel, cos
it might have given them peace of mind.” (Ed E1)
Indeed, as some staff further noted, the requirement
to follow the protocol had also presented emotional
challenges, requiring them to undertake emotion work
to try to keep patients calm:
“…they were very worried I think most of the patients
who came in. We kind of almost had to calm folk
down a little bit. We had quite a few were walking in
the door at the final visit very, very scared because
they knew it was the end of the trial and they didn’t
know what was going to happen…I was really trying
to bite my lip actually and not say to people you’ll be
alright, but I was not saying that, and it was hard,
trying to be good and do the trial properly.” (Ed C2)
Lessons learned from REPOSE: improving closeout of
future trials
“I suppose we should have discussed it more because
this trial has made us think much more about what
happens at the end and I actually think for ethical
reasons perhaps we should have discussed it more
because just because they’ve finished the trial it
doesn’t mean there aren’t ethics around it…and
thinking about it, one thing we should have thought
about is, you know, preventing patients from getting
cross.” (Dr G2)
When they reflected back on their experiences, most
staff expressed the view that the trial could have been
ended in a more carefully planned and ethically robust
way. This, as various staff members pointed out, was not
only to avoid undue distress being caused to patients
(and arguably also to themselves), but also, as some indi-
viduals noted, to promote great consistency in practices
across trial sites and, hence, alleviate their concerns that
patients had not received equal treatment at the end of
the trial.
To improve end-of-trial conduct and develop more
proactive and consistent approaches, staff highlighted
the importance of having earlier discussions involving
representatives from all of the sites. Indeed, some noted
that, had such discussions taken place, they might have
considered employing the ‘priming’ and ‘wash out’
strategies developed by those who had been involved in
the pilot:
“What I would do differently, I think we should have
shared views, I think a discussion along this line at a
trial management groups, we might really have begun
to talk about what the scenarios might be and shared
views.” (Dr B)
Staff also suggested that discussions should continue
after closeout had begun (e.g. through regular telecon-
ferences) to enable examples of good practice to be iden-
tified, develop vignettes with could be used for role-play
and training of future staff, and learn from situations
where conduct might be improved. With regards to the
latter, staff were keen to share their experiences of, and
learning from, REPOSE, particularly those who felt, with
hindsight, that end-of-trial appointments had been
mismanaged within their sites. Specifically, some staff
suggested that a lack of communication and planning
within their teams—and also the lack of clear and
detailed guidance in the SOP—had resulted in these
appointments having been conducted by individuals
(mostly lead clinicians) who had little or no knowledge
of the patients concerned. As a consequence, as Dr F
reflected, such individuals had not been cognizant of the
issues that had come up for patients during the trial and,
hence, had not always managed closeout appointments
in careful and sensitive ways:
“I just assumed everyone had come because they
wanted to do the research and isn’t that nice I get to
play with it—see that’s how I thought of it—the
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advantage is I might get to use a pump for two years
and see what it’s like. And that’s how I thought of it
when I went into the appointments, and these
patients didn’t think of it like that at all.” (Dr F)
As some staff, including Ed F2, further suggested,
receiving the news that pump therapy was to be
withdrawn from someone who was ostensibly a stranger,
and who did not necessarily have a comprehensive
knowledge of one’s clinical history and personal circum-
stances, might also have heightened patients’ negative
experiences at the end of the trial:
“…when they came back to see the doctor at that
point, that may for some of them have been the first
time they’d met that doctor as well. So it may have
been difficult for them in that respect to be told at
that point that ‘actually we don’t feel that the pump is
necessary for you’—I think some of them found that
quite hard to hear as well, the fact that they’re
meeting someone for the first time who didn’t actually
know them and they’re saying ‘actually you don’t meet
the criteria.’” (Ed F2)
Hence, staff recommended use of a team-based ap-
proach in future trials, with several individuals, including
those who patients had got to know well during the trial
(and hence who patients trusted), being involved in the
end-of-trial appointments. Such an approach, as Dr G
intimated, might help to prevent an on-going thera-
peutic relationship from being compromised:
“I would like to think that whoever is terminating
the study had been involved throughout, I think
that would make all the difference…And the last
session should have been a co-ordinated session in
which they were with their usual [diabetes health
professional] —cause even then if I’d come in as
‘this is the doctor’, they’d have been with an educa-
tor who knew them, and it would have been a very
different experience for them, it would have meant
more continuity of clinical support. We should
have turned the visit into, ‘there is a team to sup-
port you’ and that wasn’t there.’” (Dr F)
Some staff also suggested that a team-based approach
could present opportunities for staff who were anxious
about withdrawing treatment to receive support from
colleagues. In addition, as Dr G2 noted, when colleagues
had been present in the room who had known patients
during the trial, this had proved helpful because they
had been able to give advance warning of those who
were likely to be upset and angry about withdrawal of
treatment:
“I think, she [educator] knew some of the patients
better than I did because she’d done the course with
some of them. And so she was warning which ones
might be tricky. And you know, she is a good judge
of character. So that was really helpful.” (Dr G2)
Staff also noted that, to achieve an integrated, team-
based approach, funding for dedicated time should be
built into future trials because, as Ed F2 explained:
“I think one of the issues was as well is, because we’re
such busy clinical team and this was kind of fitted in
as part of our clinical work. So we didn’t have time to
do things properly.” (Ed F2)
To promote more consistent, proactive practices, staff
also suggested that, in the future, they would value a
high level of external co-ordination and support (e.g.
from a CTU) and a more detailed SOP outlining close-
out procedures—one that drew upon learning from the
REPOSE trial:
“I think everyone should have been advised to have
those difficult conversations, you know, about not
being able to keep the pump at the end, being advised
to do that at every meeting and every opportunity so
people had their expectations managed…Maybe a
reminder to meet and discuss who was going to stay
on pumps, and who wasn’t, you know, just a reminder
to say, ‘have you had that conversation within your
team? Has your patient been primed?” (Ed F3)
Alongside practical and planning issues, and given
their concerns that distress had been caused to some
patients, staff were also keen to suggest that, in future
trials, closeout procedures should be subjected to much
higher levels of ethical scrutiny. Indeed, as Dr G1 noted,
while the recruitment phase of trial is subjected to care-
ful ethical oversight to help safeguard the rights and
wellbeing of patients, a similar level of thought, planning
and accountability is not currently required at the end of
a trial:
“When you’re writing a protocol, the major thing is:
can we get enough people into the study? That’s
always the major hurdle isn’t it…with getting ethical
approval. And, in hindsight, we probably ought to
have sorted the close-out in more detail, and put time
aside to do this with amendments (to the ethics
committee) or whatever it needed.” (Dr G1)
Indeed, it was noted by this individual as well as
several others that, when the trial protocol had been
reviewed by the ethics committee, no questions and
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concerns had been raised by the potential withdrawal of
treatment from patients at the end of the trial and how
this would be managed.
Discussion
This study sought to address a neglected area in the tri-
als literature: staff experiences of closing out a clinical
trial that entailed withdrawal of treatment—insulin
pumps—from some patients. In doing so, we have
shown that, like the recruitment and implementation
phase [2–14], the ending of a trial may bring myriad
practical, ethical and emotional challenges to the fore
for staff. We have also shown that, in the absence of
clear guidelines and advance planning, staff attempted to
address these challenges in a variety of different ways,
some of which were seen to intensify their ethical con-
cerns, principally those about whether patients had been
given fair and equal treatment at the end of the trial.
At the trial’s planning stage, and when the SOP for
closeout was circulated, it was anticipated that pump
therapy would be withdrawn at the end, unless patients
met clinical criteria required for NHS funding. In actual-
ity, however, staff rarely withdrew treatment unless a
patient wanted this to happen, except in those sites
where access to local NHS funding was very restricted
and clinical criteria had to be strictly adhered to.
Whether or not they decided to withdraw pump therapy,
staff appeared to find themselves caught in a similar
ethical and moral maze to that observed by Zussman in
a study of how triaging decisions are made in intensive
care units in the USA where demand for beds outstrips
supply [24]. Specifically, staff found themselves having to
balance the interests of individuals who, by virtue of tak-
ing part in REPOSE, had become attached to a therapy
that they then wanted to retain against those of a wider
clinical (i.e. non-trial) population, which included indi-
viduals who more readily met clinical criteria for fund-
ing. Zussman has presented this conflict as being one
between Hippocratic individualism and utilitarianism—a
conflict that, he suggests, threatens the very nature of
the doctor-patient relationship [24]. In the trial context,
this conflict could equally be understood as one between
doing research and delivering clinical care, not least
because research and clinical care are themselves driven
by the conflicting paradigms of utilitarianism and Hippo-
cratic individualism. While there was some disagreement
between staff about whether an ethic of utilitarianism or
Hippocratic individualism should guide decision-making
at the end of the trial, most saw their duty of care to
REPOSE participants as having been paramount. Indeed,
staff who decided to keep most/all patients in their sites
on pumps emphasised that a desire to preserve on-going
therapeutic relationships had been central to their
decision-making, whereas those who had withdrawn
pump therapy noted damage to the therapeutic relation-
ship as a consequence and highlighted the importance of
this relationship being better protected in future trials in-
volving withdrawal of treatment. Whatever the approach
taken at the end of the trial, staff felt that the closeout of
future trials could be conducted in more ethically robust
and considered ways. To achieve this, most also suggested
this aspect of trial work should be subjected to greater
ethical scrutiny and oversight.
While clinical trials are subjected to external ethical
oversight, the recruitment phase, as Petryna [17] has
observed, tends to be where most attention, reflection
and ethical debate are focussed, this also being a concern
voiced by Fisher in a powerful and thought-provoking
exposition of the pharmaceutical trials industry in the
USA. In this, she notes that bioethical reflection tends to
concentrate on helping to ensure consent to take part in
a trial is given freely and willingly to the possible detri-
ment of what happens later on in the trial: “Oftentimes,
bioethicists are concerned about reducing the coercion
of prospective human subjects, but there is also a danger
in exploiting individuals if they are not sufficiently
rewarded for their investment of time and exposure to
risk” (p 125) [10]. In keeping with these kinds of con-
cerns, staff in our study shared their worries that upset
and distress had been caused to some individuals at the
end of the trial, especially those from whom treatment
was withdrawn. Most staff also expressed the view that,
had there been more advanced planning and discussion,
and greater accountability to an ethics committee, some
of this distress could have been reduced, if not avoided
altogether. Hence, staff saw their participation in this
interview study as an important opportunity to raise
awareness of the ethical and other difficulties they had
encountered and expressed the hope that the findings
would be used to help improve the (ethical) conduct of
future clinical trials involving withdrawal of treatment.
A key finding from this study is that some of the same
ethical issues that may vex staff at the outset of the trial
may carry over to, or re-present themselves at, its end as
well as there being potential for new ethical consider-
ations and challenges to arise. For instance, when staff
tried to make sense of patients’ upset, anger and distress,
they reflected upon the possibility that some individuals
who were most resistant to withdrawal of pump therapy
might have been under the influence of the therapeutic
misconception [21], a phenomenon that has been ob-
served in empirical research undertaken with patients
[25, 26]. As staff observed, this was because REPOSE
participants appeared to hold strong and recalcitrant
views that the (pump) treatment to which they had been
allocated had been most therapeutically suited to them.
Indeed, it was noted that, if patients did believe that they
had received treatment that had been needs driven, it
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was entirely understandable that they might have felt
staff had failed them in a duty of care by withdrawing
this treatment at the end of the trial. While other pa-
tients, as staff suggested, might not have initially seen
pump therapy as being a better treatment than an injec-
tion regimen, many appeared to shift their perceptions as
the trial progressed by virtue of having experienced un-
anticipated (non-clinical) benefits from using a pump.
This issue, as staff pointed out, had had important, and
initially unanticipated, ethical and emotional repercus-
sions. First, because it led them to question whether pa-
tients’ consent to take part in a trial involving possible
withdrawal of treatment remained valid at the end, a ques-
tion that has prompted others to recommend researching
patients’ ‘whole-trial’ experiences to better understand the
unanticipated (ethical) harms, as well as benefits, that may
arise from trial participation [26]. Second, because some
of the patients whom staff had closed out from the trial
expressed the view that the non-therapeutic benefits they
had gained from using a pump should guide treatment
decision-making, rather than this being driven by formal
clinical criteria. Indeed, although only caveated interpreta-
tions can be drawn from staff ’s accounts, it is possible that
patients might have been experiencing a form of thera-
peutic misconception at the end of the trial in so far as
they appeared to expect staff to tailor treatment to their
personal needs rather than to follow a standardised proto-
col. It is regrettable that it was not possible to interview
patients for this study because of the lengthy time re-
quired to obtain the necessary approvals. However, re-
search undertaken by Wynne [27] with people with
multiple sclerosis who took part in a trial of hyperbaric
oxygen therapy appears to support staff ’s speculations and
concerns. Wynne observed that most patients wanted to
remain on this therapy, despite the trial failing to show
clinical efficacy, because they saw themselves as having
gained benefits that were substantively different from
those that the trial set out to formally assess. Notably, in
Wynne’s study, patients felt so strongly that they should
remain on hyperbaric oxygen therapy that they made in-
dependent financial arrangements for treatment following
the trial.
Conflicts between research and clinical care, which
have been shown to vex and challenge staff at earlier
stages in the trial process [5, 8], with ensuing emotional
consequences [7, 16], also appeared to re-present them-
selves at the end of the REPOSE trial. For instance, some
staff expressed their concerns that they had failed pa-
tients in their duty of care because the trial protocol had
not permitted them to disclose treatment decisions until
after final trial data had been collected. Others voiced
frustrations that, because of the requirement to follow
the trial protocol, they had been unable to offer patients
optimal and individualised clinical care, which might
have enabled them to gain greater clinical benefit from
using a pump. To address this concern, staff also de-
scribed allowing some patients to remain on pump ther-
apy following the trial, despite these individuals having
not met clinical eligibility criteria. Indeed, a desire to
reconcile the conflict between research and clinical care
appeared paramount to staff decision-making in these
specific instances, and more generally when patients
were allowed to keep their pump, with staff emphasising
that they would have failed patients in a duty of care had
they removed pumps when it was possible to access on-
going funding. While these staff thus presented powerful
and convincing ethical justifications for their decision-
making, which principally cohered around their desire to
preserve on-going therapeutic relationships, it is also
possible that they might have used these justifications as
post-hoc rationalisations to present themselves in a mor-
ally favourable light [28]. Rather than speculating further
on this potentially delicate matter, what is perhaps more
helpful and salient to note is that the (ethical) conduct
of these staff was questioned by other members of the
co-investigator team; especially those who had followed
the protocol and withdrawn treatment from patients
who did not meet clinical eligibility criteria. These indi-
viduals speculated that, as well as prioritising the inter-
ests of individual patients over those of the wider
diabetes population (an ethical standpoint that was
sometimes antithetical to their own), their colleagues
might have been attempting to avoid the physical and
emotional work involved in reverting patients back to
injection regimens. In doing so, these individuals not
only raised important questions about whether patients
across the sites were treated fairly and equally at the end
of the trial, their accounts also made apparent that in-
consistent practices could be a source of friction within
the trial team.
Conclusion
The Declaration of Helsinki now requires that “re-
searchers and host country governments should make
provisions for post-trial access for all participants who
still need an intervention identified as beneficial in the
trial” [29]. While this is clearly an important step to-
wards safeguarding patients’ rights and interests, import-
ant questions remain about those individuals who do
not gain clinical benefit from a trial intervention but
who nonetheless feel they have gained personal benefits.
As the findings of this study powerfully highlight, there
may be no simple answers or easy solutions to offer—in-
deed, staff found themselves torn between an ethic of
Hippocratic individualism and one of utilitarianism.
Clearly only limited conclusions can be drawn from one
study, and it is vital that further research be undertaken
on staff and patients’ closeout experiences. However, a
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key learning point from the REPOSE trial is that more
thought, planning and ethical oversight should go into
the design and conduct of future trials involving
withdrawal of treatment(s); indeed, staff were keen to
cascade their experiences with this agenda in mind. In
particular, staff wanted others to learn from examples of
what had worked in their particular sites (e.g. priming
patients for withdrawal of treatment; offering wash out
strategies to allow patients to adjust practically and psy-
chologically to treatment withdrawal) as well as those
that had not (e.g. having an individual rather than a
team involved in the appointments where treatment was
withdrawn). While, in doing so, staff emphasised their
ethical responsibilities to their own and future patients,
we would argue that there should also be an ethical
responsibility to trial staff to offer them better guidance,
input and support. Indeed, as our interviews made only
too apparent, not only did the ending of the trial cause
distress to some patients, it also had a significant
emotional impact on staff, leaving some feeling isolated,
overwhelmed, unsupported and sometimes also resentful.
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